Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,118.00
Ask: 12,122.00
Change: -72.00 (-0.59%)
Spread: 4.00 (0.033%)
Open: 12,304.00
High: 12,356.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

Tue, 21st May 2024 09:04

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

The FTSE 100 index opened down 29.22 points, 0.4%, at 8,394.98. The FTSE 250 was down 86.45 points, 0.4%, at 20,786.88. The AIM All-Share fell 2.67 points, 0.3%, at 807.27.

The Cboe UK 100 was down 0.4% at 837.69, the Cboe UK 250 was down 0.3%, trading at 18,205.44, and the Cboe Small Companies was largely flat at 16,525.42.

In European equities on Tuesday, the CAC 40 in Paris was down 0.5%, while the DAX 40 in Frankfurt fell 0.2%.

In Asia, the Shanghai Composite ended down 0.4%, while the Hang Seng in Hong Kong was 2.1% lower. In Tokyo, the Nikkei 225 fell 0.3%, while Sydney's S&P/ASX 200 ended 0.2% lower.

"European markets are in the red, taking their cues from declines in Asia overnight," interactive investor analyst Victoria Scholar commented.

The pound was quoted at USD1.2718 early Tuesday in London, up from USD1.2702 at the time of the European equities close Monday. The euro stood at USD1.0866, up slightly from USD1.0862. Against the yen, the dollar was trading at JPY156.12, largely unmoved from JPY156.14.

Speaking at a conference in the US state of Florida on Monday, Fed vice chair for supervision Michael Barr said the bank had made "tremendous progress" in bringing inflation down from its 2022 peak, while unemployment – the other leg of its dual mandate – had remained low.

"We are not yet all the way to our target of 2%," he said in prepared remarks, noting the "disappointing" recent inflation data.

"These results did not provide me with the increased confidence that I was hoping to find to support easing monetary policy by reducing the federal funds rate," he said.

"This means that we will need to allow our restrictive policy some further time to continue to do its work," added Barr, a permanent voting member of the Fed's rate-setting committee.

Also speaking Monday, Fed Vice Chair Philip Jefferson – another permanent voting member of the Fed's rate-setting committee – said inflation was still coming down, "although nowhere near as quickly as I would have liked."

"In making judgments about the appropriate stance of policy rate over time, I will be carefully assessing the incoming data, the evolving outlook, and the balance of risks," he said in prepared remarks for a conference in New York.

Gold was quoted at USD2,414.12 an ounce early Tuesday, down from USD2,423.50 late Monday afternoon. Brent oil was quoted at USD83.13 a barrel, falling from USD83.65.

Swissquote analyst Ipek Ozkardeskaya said "record US production and comfortable spare capacity from Opec" are keeping a lid on oil prices, despite "Middle East tensions, rebound in Chinese industrial production [and] the reflation trade that's supported by the prospects of central bank rate cuts".

In London, AstraZeneca shares rose 0.6% after it set out its ambition to achieve USD80 billion in annual revenue by the end of the decade, as it signalled a new "era of growth".

The target, which the Cambridge pharmaceuticals manufacturer firm described as "bold," would represent a 75% jump from the USD45.81 billion it achieved in 2023.

AstraZeneca said it would meet its aim by bolstering its oncology offering and rare disease portfolio, and launching 20 new treatments before the end of the decade.

Speaking ahead of an investor day, Chief Executive Officer Pascal Soriot said: "Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious USD45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for USD80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than USD5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade."

AstraZeneca said as it continues to grow across all therapy areas, and will continue to decouple its carbon emissions from its increase in revenue.

Entain fell 1.1%. It backed its "portfolio of diversified" assets, as it reported the conclusion of a strategic review on Tuesday, opting to hold on to its brands, save for a non-core offering in Georgia.

The Ladbrokes owner had kicked off the strategic probe in January "with the objective of maximising shareholder value".

The firm said on Tuesday: "Entain has the appropriate portfolio of diversified strategic assets, brands, capabilities and geographic footprint to ensure it is well positioned to deliver high quality long term growth. There remains significant upside by focusing on delivery of the group's strategy of returning to organic revenue growth, expanding margins and winning in the US."

Aside from Ladbrokes, Entain also owns the Coral, bwin and PartyPoker brands, all units it will hang on to. It is open to a sale of Crystalbet, however, a "non-core" gaming brand in Georgia.

"Strategic alternatives for this business will be considered, including interest already received from potential acquirers," Entain said.

Entain noted the strategic review considered recent developments in key markets. This included Brazil returning to growth and a "levelling of the regulatory playing field in the UK", where it also expects to resume growth later this year.

"Delivery of the product roadmap for BetMGM is progressing well, including recently launched MLB and NBA sports betting markets supported by Angstrom's unique capabilities, particularly in parlay products," Entain said on the joint-venture co-owned by one-time suitor MGM Resorts International.

The firm also celebrated the Nevada Gaming Commission last week Thursday approving a licence application "without limitation".

SSP declined 8.3%. It reported a rise in half-year, though a decline in profit. Its net debt also grew. SSP outlined a positive outlook, however, expecting a boost from a summer of sport.

The operator of food and beverage outlets in travel locations said revenue in the half-year to March 31 rose 15% to GBP1.52 billion from GBP1.32 billion a year prior. Pretax profit, however, fell 19% to GBP12.8 million from GBP15.8 million. Hurting its bottom line, finance income declined 21% to GBP8.9 million, while finance expenses rose 17% to GBP54.4 million.

SSP declared an interim dividend of 1.2 pence per share. It did not pay a first-half dividend a year prior. It had returned to the dividend list with a final dividend for the previous financial year. That was its first dividend since the onset of the pandemic.

CEO Patrick Coveney said: "Trading momentum has continued into the second half, and we are confident in delivering on our expectations for the full year. In particular, we are well set to capitalise on what we anticipate will be a Summer of strong demand in all our markets - including Continental Europe, where the Olympics and the European Championships will help boost footfall in airports and stations. We will also start to realise the benefit of our latest value-creating acquisition in Australia and new market entries in New Zealand and Indonesia."

The firm's net debt increased to GBP619 million from GBP297 million a year prior, it said.

Also on the decline, Shoe Zone slumped 10%. The retailer now expects annual pretax profit of GBP13.8 million, lower than its original outlook of GBP15.2 million.

"At the point at which the original forecast was prepared the consensus was that the national living wage would increase to GBP11.08, but when announced, the increase was to GBP11.44 which adds GBP400,000 of cost in our second half. The continuing disruption in the Middle East has increased shipping times and container prices which adds a minimum of GBP500,000 of cost and due to the large number of stores we have closed, particularly in Scotland, we have provided for an additional GBP500,000 of dilapidations," it explained.

Revenue in the half year to March 30 rose 1.5% to GBP76.5 million from GBP75.4 million 12 months earlier. Pretax profit rose 71% to GBP2.6 million from GBP1.5 million.

It maintained its interim dividend at 2.5 pence per share.

XP Power shares jumped 46% to 1,702.00p after it received takeover interest from Nasdaq-listed Advanced Energy Industries.

Advanced Energy Industries is a maker of precision power conversion, measurement, and control solutions. AEI said it has made three all-cash takeover approaches, each slightly higher than the last. The first offer in October valued XP Power's equity at GBP339 million, a second roughly two weeks later in November value it at GBP369 million and the most recent, earlier this month, valued it at GBP468 million. Including debt, the latest proposal has a total value of GBP571 million.

At GBP19.50 per share, the latest proposal is a 68% premium to power control systems maker XP Power's closing price of GBP11.64 on Monday.

Advanced Energy Industries hit out at the "lack of engagement" from XP Power.

AEI said: "Each of these proposals has been at a significant premium to the share price at the time of each respective proposal, but the board of XP Power unanimously rejected each of these proposals. Given the lack of engagement from the board of XP Power, Advanced Energy believes that XP Power's shareholders should be made aware of the latest proposal, which represents a compelling and highly attractive opportunity."

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.